A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

Phase 1

Completed

• Conditions: Advanced Solid Tumors; Melanoma; Cancer; Oncology; Oncology Patients; Tumors; Advanced Malignancy
• Interventions: Drug: AMG 232; Drug: Trametinib; Drug: Dabrafenib

• Registration Number: NCT02110355
• Lead Sponsor: Kartos Therapeutics, Inc.

Brief Summary

Phase 1b/2a, open-label, sequential dose escalation and expansion study of AMG 232 in combination with trametinib and dabrafenib in subjects with metastatic melanoma followed by a direct comparison of AMG 232 combined with trametinib and dabrafenib versus trametinib combined with dabrafenib alone.

Detailed Description

The study will be conducted in 3 parts: Part 1 - Dose Escalation, Part 2 - Dose Expansion and Part 3, a randomized Phase 2a.

In both part 1 and 2, subjects will be enrolled open-label into 1 of 2 arms. For both Arm 1 and Arm 2, the part 1 dose escalation is aimed at determining an AMG 232 maximum tolerated dose (MTD) with a fixed dose of the combination drug(s) and evaluating safety, tolerability, pharmacokinetics and pharmacodynamics of each combination. Part 2 dose expansion will enroll subjects to receive therapy with a dose and schedule of AMG 232 selected from the corresponding part 1 dose escalation. In part 2 subjects will be enrolled to confirm safety and tolerability and to assess clinical activity prior to proceeding to Part 3, Phase 2a. In Phase 2a, Subjects will be randomized open-label in a 1:1 ratio to receive AMG 232 in combination with trametinib plus dabrafenib versus trametinib plus dabrafenib alone.

Only Part 1 of the study was enrolled and the study did not proceed into Phase 2.

Study Timeline

• Study First Submitted: 2014-04-08
• Study First Submitted QC: 2014-04-08
• Study First Posted: 2014-04-10
• Study Start: 2014-12-19
• Primary Completion: 2018-12-27
• Study Completion: 2018-12-27
• Status Verified: 2021-03
• Last Update Submitted: 2021-03-24
• Last Update Posted: 2021-03-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 31

Inclusion Criteria

Subjects must have histologically or cytologically confirmed metastatic cutaneous or mucosal melanoma, Able to swallow and retain orally administered medication, Adequate hematological, renal, hepatic, and coagulation laboratory assessments

Exclusion Criteria

Clinically significant bleeding within 4 weeks of screening, Current use of warfarin, factor Xa inhibitors, and direct thrombin inhibitors, Infection requiring anti-infective treatments within 1 week of study enrollment, Anti-tumor therapy, Major surgery within 28 days

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
AMG 232 with Trametinib	AMG 232	Arm 2 of Part 1 and 2
AMG 232 with Trametinib and Dabrabenib	AMG 232	Arm 1 of Part 1 and 2 and Part 3
AMG 232 with Trametinib and Dabrabenib	Dabrafenib	Arm 1 of Part 1 and 2 and Part 3
AMG 232 with Trametinib and Dabrabenib	Trametinib	Arm 1 of Part 1 and 2 and Part 3
AMG 232 with Trametinib	Trametinib	Arm 2 of Part 1 and 2
Trametinib and Dabrafenib	Dabrafenib	Part 3
Trametinib and Dabrafenib	Trametinib	Part 3

Primary Outcome Measures

Name	Time	Method
Subject incidence of treatment-emergent adverse events, Results of safety laboratory tests, vital sign measurements, ECG measurements, PK parameters; Progression-free Survival Rate	36 months	Incidence and grade of treatment-emergent adverse events, including dose-limiting toxicities; AMG 232, trametinib, dabrafenib, and metabolite PK parameters; progression-free Survival

Secondary Outcome Measures

Name	Time	Method
Time to and duration of overall response and duration of stable disease measured by CT or MRI and assessed per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1, Progression-free and Overall Survival	36 months	Objective Tumor Response

Trial Locations

Locations (1)

Research Site; 🇦🇺 Melbourne, Victoria, Australia